The Chemistry of Bioconjugation in Nanoparticles-Based Drug Delivery System

Werengowska-Ciećwierz, Karolina; Wiśniewski, Marek; Terzyk, Artur P.; Furmaniak, Sylwester

doi:10.1155/2015/198175

Cited by 86 publications

(55 citation statements)

References 197 publications

(300 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibodies raised against these targets can be attached to nanocarriers to assist accumulation at the tumor site. 57 Examples of such receptors include vascular endothelial growth factor receptor, VEGFR, which is expressed by the endothelial cells of growing blood vessels, as typically found in [58][59][60] This form of targeting is relatively simple to achieve with surface modification of the nanoparticle (reviewed in 61 and has formed part of a number of targeted cisplatin nanoparticles strategies. 57,[62][63][64] However, there are some important considerations:…”

Section: Active Targetingmentioning

confidence: 99%

Drug Delivery Strategies for Platinum-Based Chemotherapy

Browning

Reardon²,

Parhizkar³

et al. 2017

ACS Nano

196

129

View full text Add to dashboard Cite

Few chemotherapeutics have had such an impact on cancer management as cis-diamminedichloridoplatinum(II) (CDDP), also known as cisplatin. The first member of the platinum-based drug family, CDDP's potent toxicity in disrupting DNA replication has led to its widespread use in multidrug therapies, with particular benefit in patients with testicular cancers. However, CDDP also produces significant side effects that limit the maximum systemic dose. Various strategies have been developed to address this challenge including encapsulation within micro- or nanocarriers and the use of external stimuli such as ultrasound to promote uptake and release. The aim of this review is to look at these strategies and recent scientific and clinical developments.

show abstract

Section: Active Targetingmentioning

confidence: 99%

Drug Delivery Strategies for Platinum-Based Chemotherapy

Browning

Reardon²,

Parhizkar³

et al. 2017

ACS Nano

196

129

View full text Add to dashboard Cite

show abstract

“…This evolving and interdisciplinary field mainly involves the design, characterization, manufacture, manipulation and applications of structures at the nanometer scale (nano: one billionth). Such structures are known as nanoparticles and are of particular interest as seen by the growing popularity and publications on nanoparticles or nanomaterials [47][48][49]. These can be attributed to their physicochemical features among those are their rigidity, hydrophobicity, size and charge, which portray this technology as tremendously potent in solving societal issues including health-related ones [50].…”

Section: Nanomedicine For Better Cancer Therapymentioning

confidence: 99%

Nano-Mediated Photodynamic Therapy for Cancer: Enhancement of Cancer Specificity and Therapeutic Effects

Tynga

Abrahamse

2018

Preprint

View full text Add to dashboard Cite

Deregulation of cell growth and development lead to cancer, a severe condition that claims millions of lives worldwide. Targeted or selective approaches used during cancer treatment determine the efficacy and outcome of the therapy. In order to enhance specificity and targeting and better treatment options for cancer, novel and alternative modalities are currently under development. Photodynamic therapy has the potential to eradicate cancer and combination therapy would yield even greater outcomes. Nanomedicine-aided cancer therapy shows enhanced specificity for cancer cells and minimal side-effects coupled with effective cancer destruction both in vitro and in vivo. Nanocarriers used in drug-delivery systems are well able to penetrate cancer stem cell niche, simultaneously killing cancer cells and eradicate drug-resistant cancer stem cells, yielding therapeutic efficiency up to 100 fold against drug-resistant cancer in comparison with free drugs. Safety precautions should be considered when using Nano-mediated therapy as the effects of extended exposure to biological environments are still to be determined.

show abstract

“…This reaction occurs in two stages, initially to create EDC (1-ethyl-3- (3-dimethylaminopropyl) carbodiimide) on the carboxyl group that is present on the nanoparticle surface to form an intermediate reactive species towards primary amines [336]. Recently, other conjugation methods introduced an N-hydroxysulfosuccinimide (NHS) linker in a second step such as sulfo-NHS to produce a more stable intermediate in order to improve reaction efficiency [337].…”

Section: Conjugation Strategies To Functionalize Nanocarriersmentioning

confidence: 99%

Ligand-targeted theranostic nanomedicines against cancer

Yao¹,

D’Angelo²,

Butler

et al. 2016

Journal of Controlled Release

164

View full text Add to dashboard Cite

Nanomedicines have significant potential for cancer treatment. Although the majority of nanomedicines currently tested in clinical trials utilize simple, biocompatible liposome-based nanocarriers, their widespread use is limited by non-specificity and low target site concentration and thus, do not provide a substantial clinical advantage over conventional, systemic chemotherapy. In the past 20 years, we have identified specific receptors expressed on the surfaces of tumor endothelial and perivascular cells, tumor cells, the extracellular matrix and stromal cells using combinatorial peptide libraries displayed on bacteriophage. These studies corroborate the notion that unique receptor proteins such as IL-11Rα, GRP78, EphA5, among others, are differentially overexpressed in tumors and present opportunities to deliver tumor-specific therapeutic drugs. By using peptides that bind to tumor-specific cell-surface receptors, therapeutic agents such as apoptotic peptides, suicide genes, imaging dyes or chemotherapeutics can be precisely and systemically delivered to reduce tumor growth in vivo, without harming healthy cells. Given the clinical applicability of peptide-based therapeutics, targeted delivery of nanocarriers loaded with therapeutic cargos seems plausible. We propose a modular design of a functionalized protocell in which a tumor-targeting moiety, such as a peptide or recombinant human antibody single chain variable fragment (scFv), is conjugated to a lipid bilayer surrounding a silica-based nanocarrier core containing a protected therapeutic cargo. The functionalized protocell can be tailored to a specific cancer subtype and treatment regimen by exchanging the tumor-targeting moiety and/or therapeutic cargo or used in combination to create unique, theranostic agents. In this review, we summarize the identification of tumor-specific receptors through combinatorial phage display technology and the use of antibody display selection to identify recombinant human scFvs against these tumor-specific receptors. We compare the characteristics of different types of simple and complex nanocarriers, and discuss potential types of therapeutic cargos and conjugation strategies. The modular design of functionalized protocells may improve the efficacy and safety of nanomedicines for future cancer therapy.

show abstract

The Chemistry of Bioconjugation in Nanoparticles-Based Drug Delivery System

Cited by 86 publications

References 197 publications

Drug Delivery Strategies for Platinum-Based Chemotherapy

Drug Delivery Strategies for Platinum-Based Chemotherapy

Nano-Mediated Photodynamic Therapy for Cancer: Enhancement of Cancer Specificity and Therapeutic Effects

Ligand-targeted theranostic nanomedicines against cancer

Contact Info

Product

Resources

About